FDA extends priority review of Merck KGaA's MS pill
November 26, 2010 at 02:27 AM EST
FRANKFURT, Nov 26 (Reuters) - The U.S. drugs watchdog will take more time to decide over Merck KGaA's multiple sclerosis (MS) pill, the German company said on Friday, two months after drawing a rejection from European regulators.